ABCELLERA CLOSES SERIES A LED BY DCVC BIO.

 
FREE EXCERPT

AbCellera has closed its Series A financing led by DCVC Bio, a Silicon Valley venture capital fund focused on deep technology ventures that lie at the nexus of artificial intelligence and biotechnology. AbCellera will use the USD $10 million financing to accelerate the growth of their therapeutic antibody discovery business, including investments to build capacity and integration of advanced technological capabilities spanning computation, protein engineering, and immune repertoire profiling.

With this financing, we will double-down on our partnership business that has enjoyed profitable, triple- digit growth over the past 3 years. In DCVC Bio, we have found the ideal funding partner to help us accelerate the success of our full-stack antibody discovery engine, one that integrates artificial intelligence with industry- leading microfluidic screening technology, said Carl Hansen, CEO of AbCellera.

AbCellera's high-throughput single B cell screening platform and repertoire sequencing technologies enable discovery of large multidimensional data sets of valuable antibody sequences. AbCellera applies machine learning algorithms and custom data visualization tools to optimize lead selection, accelerate discovery, and unlock previously inaccessible targets, for a wide range of therapeutic modalities.

In connection with the investment, John Hamer, Managing Partner at DCVC Bio, has joined AbCellera's Board of Directors, along with AbCellera Co-Founder Veronique Lecault. Doug Janzen will be stepping down from his role as Chairman of the Board.

Carl and his team have built the kind of company we love to back. They continue to drive internal innovation and attract top quality partners from across the industry. Their disruptive discovery engine has empowered top-tier biotechs, helping them to move their programs more quickly towards the clinic, and has succeeded against some of the most challenging therapeutic targets faced by global pharma. AbCellera's fresh and cross-disciplinary approach exemplifies the computationally advantaged platforms we seek, said DCVC Bio Managing Partner Dr. John Hamer.

We are pleased to bring John Hamer and Veronique Lecault onto AbCellera's Board, said Hansen. John brings a rare combination of deep scientific expertise...

To continue reading

FREE SIGN UP